Bamco Inc. NY Sells 11,174 Shares of argenx SE (NASDAQ:ARGX)

Bamco Inc. NY lowered its holdings in argenx SE (NASDAQ:ARGX) by 4.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 250,304 shares of the company’s stock after selling 11,174 shares during the quarter. Bamco Inc. NY owned about 0.42% of argenx worth $135,685,000 at the end of the most recent quarter.

Other institutional investors have also recently bought and sold shares of the company. Profund Advisors LLC raised its stake in shares of argenx by 3.0% in the second quarter. Profund Advisors LLC now owns 973 shares of the company’s stock worth $418,000 after purchasing an additional 28 shares during the last quarter. Raymond James Trust N.A. grew its holdings in argenx by 6.0% during the third quarter. Raymond James Trust N.A. now owns 495 shares of the company’s stock worth $268,000 after buying an additional 28 shares in the last quarter. Wealth Alliance raised its position in argenx by 4.8% in the 2nd quarter. Wealth Alliance now owns 628 shares of the company’s stock valued at $270,000 after buying an additional 29 shares during the last quarter. GAMMA Investing LLC lifted its stake in argenx by 51.3% during the 2nd quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after acquiring an additional 40 shares in the last quarter. Finally, Hantz Financial Services Inc. boosted its holdings in argenx by 8.9% during the 3rd quarter. Hantz Financial Services Inc. now owns 528 shares of the company’s stock worth $286,000 after acquiring an additional 43 shares during the last quarter. Institutional investors and hedge funds own 60.32% of the company’s stock.

Analyst Upgrades and Downgrades

Several analysts have recently commented on the stock. Raymond James reiterated a “strong-buy” rating and issued a $605.00 target price on shares of argenx in a report on Thursday, October 10th. Deutsche Bank Aktiengesellschaft downgraded shares of argenx from a “buy” rating to a “hold” rating in a research report on Friday, October 4th. JPMorgan Chase & Co. lifted their target price on shares of argenx from $640.00 to $670.00 and gave the stock an “overweight” rating in a research report on Monday, November 4th. HC Wainwright restated a “buy” rating and issued a $617.00 target price on shares of argenx in a research note on Wednesday, November 20th. Finally, Piper Sandler increased their price target on argenx from $553.00 to $620.00 and gave the company an “overweight” rating in a research report on Friday, November 1st. Three analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average target price of $630.42.

argenx Stock Up 0.3 %

Shares of NASDAQ:ARGX opened at $616.55 on Monday. The firm has a market capitalization of $37.22 billion, a PE ratio of -700.63 and a beta of 0.61. The company has a 50-day moving average price of $565.73 and a two-hundred day moving average price of $497.22. argenx SE has a twelve month low of $327.73 and a twelve month high of $620.28.

argenx (NASDAQ:ARGX) last announced its quarterly earnings results on Thursday, October 31st. The company reported $1.39 EPS for the quarter, beating analysts’ consensus estimates of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The company had revenue of $588.88 million for the quarter, compared to analysts’ expectations of $543.29 million. During the same period in the prior year, the company posted ($1.25) EPS. Analysts anticipate that argenx SE will post 2.2 earnings per share for the current fiscal year.

argenx Company Profile

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.